Liver Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 14, 2005; 11(10): 1433-1438
Published online Mar 14, 2005. doi: 10.3748/wjg.v11.i10.1433
Figure 1
Figure 1 Staging of hepatocellular carcinoma before and after TAE. Twenty-nine patients received embolization before liver transplantation. Seven patients exceeding criteria (group A2) (outside the box) were downgraded to acceptable limits (inside the box with arrow).
Figure 2
Figure 2 The 5-year actuarial survival rate of patients with hepatocellular carcinoma after liver transplantation.
Figure 3
Figure 3 Patient and graft survival by Kaplan-Meier analysis shows higher 4-year survival in hepatocellular carcinoma that received pre-transplantation TAE (group A) compared to non-TAE (group B). Log-rank: P = 0.95.
Figure 4
Figure 4 Patient and graft survival by Kaplan-Meier analysis shows a higher 3-year survival in patients with hepatocellular carcinoma previously above the Milan criteria and downgraded by TAE (group A2) than the patients that originally met the criteria (group A1 + group B). Log-rank: P = 0.81.
Figure 5
Figure 5 Patient and graft survival by Kaplan-Meier analysis shows a significantly higher 3-year survival in patients with hepatocellular carcinoma with tumor necrosis >85% compared to those with tumor necrosis <85% after TAE. Log-rank: P = 0.060.